ARTICLE | Clinical News

Axicabtagene ciloleucel regulatory update

December 22, 2016 8:09 PM UTC

Kite began submission of a rolling BLA to FDA for axicabtagene ciloleucel to treat relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL) in patients who are ineligible for autologous s...

BCIQ Company Profiles

Kite Pharma Inc.

BCIQ Target Profiles